Feb. 27 at 10:24 PM
$IMNN with strong Phase 2b
has a good future
in licensing negotiations, pricing and terms are directly linked to the buyer’s risk and the costs of bringing the project to market. If the buyer knows that a single pivotal study may be sufficient, their projected capital requirements decrease while their risk assessment is revised downward. In addition, the time to potential market approval—and thus to revenues—is shortened.
